Politique ou Programme

• Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as it relates to reimbursement recommendations decision-making process and framework.
• Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
• Science and Technology Strategy, Advantage Canada or any Government policy or program initiatives to help support more Research and Development conducted in Canada, advocate for the development of a coordinated life science strategy

Politique ou Programme, Règlement

• Subsequent Entry Biologics (SEBs) and Orphan Drugs framework: seeking an approval framework supported and protected by Regulations in harmonization with other developed countries

Proposition législative, Projet de loi ou résolution, Règlement

• Patent Act as it relates to the implementation of the Comprehensive Economic Trade Agreement (CETA) and its Intellectual property protection provisions.
• The international trade negotiations under the Tans-Pacific Partnership (TPP) as it relates to potential legislative or regulatory changes of Canada's intellectual property regime for pharmaceutical products (Patent Act).

Règlement

• Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
• Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for therapeutic products.
• The implementation of all the upcoming regulations related to Bill C-17, formerly known as an Act to Amend the Food and Drugs Act

Subvention, Contribution ou autre avantage financier

• National Immunization Strategy. Advocacy to seek continued funding in vaccines.